164 related articles for article (PubMed ID: 26694130)
1. Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
Tsurusawa M; Watanabe T; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Sekimizu M; Koh K; Kosaka Y; Komada Y; Saito AM; Nakazawa A; Horibe K;
Leuk Lymphoma; 2016 Jul; 57(7):1657-64. PubMed ID: 26694130
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
3. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
[TBL] [Abstract][Full Text] [Related]
4. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
5. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL.
Little MA; Morland B; Chisholm J; Hole A; Shankar A; Devine T; Easlea D; Meyer LC; Pinkerton CR
Med Pediatr Oncol; 2002 Feb; 38(2):98-103. PubMed ID: 11813173
[TBL] [Abstract][Full Text] [Related]
6. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
Yakushijin Y; Shikata H; Takaoka I; Horikawa T; Takeuchi K; Yamanouchi J; Azuma T; Narumi H; Hato T; Yasukawa M
Int J Clin Oncol; 2011 Apr; 16(2):118-24. PubMed ID: 20924633
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
Kushner BH; Heller G; Kramer K; Cheung NK
Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
[TBL] [Abstract][Full Text] [Related]
8. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
Rubino C; Laplanche A; Patte C; Michon J
J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.
Inaba H; Cao X; Pounds S; Pui CH; Rubnitz JE; Ribeiro RC; Razzouk BI
Cancer; 2011 Mar; 117(6):1313-20. PubMed ID: 21381017
[TBL] [Abstract][Full Text] [Related]
10. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
11. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia.
Delorme J; Badin S; Le Corroller AG; Auvrignon AA; Auclerc MF; Gandemer V; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Berthou C; Bauduer F; Pautard B; Vannier JP; Braguer D; Leblanc T; Leverger G; Baruchel A; Michel G
J Pediatr Hematol Oncol; 2003 Jun; 25(6):441-7. PubMed ID: 12794521
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
[TBL] [Abstract][Full Text] [Related]
15. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
16. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
17. [Use of filgrastim (RHU G-CSF) in supplemental treatment of non Hodgkin's lymphoma (NHL) in children].
Rokicka-Milewska R; Derulska D; Sopyło B; Gadomski A; Dziedzic A
Pol Arch Med Wewn; 1994 May; 91(5):367-75. PubMed ID: 7521959
[TBL] [Abstract][Full Text] [Related]
18. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
Graczyk J; Cheung MC; Buckstein R; Chan K
Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
